Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ch225-IL2
- Development stage
- Unknown
- Lead developer
- Scripps Research
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Parenteral
01
Overview
**ch225-IL2** is an experimental EGFR-targeted immunocytokine consisting of a mouse-human chimeric anti-epidermal growth factor receptor antibody derived from mAb 225, with human interleukin-2 genetically fused to the antibody heavy-chain C-terminus. The antibody component targets EGFR-expressing tumor cells and can block ligand-driven EGFR signaling, while the IL-2 payload activates IL-2 receptor-expressing immune effector cells, including activated T cells and natural killer cells. In preclinical human melanoma xenograft models reconstituted with human lymphokine-activated killer cells, ch225-IL2 eradicated established hepatic and pulmonary micrometastases and improved survival relative to separately administered antibody plus recombinant IL-2. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/8144194/))
- Other names
- ch225-IL2ch-225-IL2ch 225-IL2ch225-IL-2ch-225-IL-2ch 225-IL-2
02
Targets
IL2RB (IL-2 receptor beta chain)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on ch225-IL2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ch225-IL2.